Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

Summary

A Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older

Timeline

Start

2021-08-25

Primary completion

2022-02-08

Completion

2023-06-14

Drugs

Indications